Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 15/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2221216 | 0.93 | OXTR (0.35) | OXTROPRM1TP53PPARGPPARA | |
| SCHEMBL2220848 | 0.85 | TP53 (0.43) | TP53RXFP1 | |
| SCHEMBL2220117 | 0.85 | CYP2C9 (0.41) | OPRM1TP53RXFP1 | |
| SCHEMBL2268157 | 0.83 | TP53 (0.36) | TP53RXFP1 | |
| SCHEMBL2365403 | 0.83 | OPRM1 (0.38) | OPRM1TP53RXFP1PPARGPPARA | |
| SCHEMBL13274535 | 0.82 | TP53 (0.37) | TP53RXFP1 | |
| SCHEMBL2220259 | 0.82 | TP53 (0.36) | TP53RXFP1 | |
| SCHEMBL2222072 | 0.82 | MEN1 (0.39) | OPRM1TP53RXFP1 | |
| SCHEMBL2221942 | 0.81 | ENPP2 (0.35) | TP53RXFP1 | |
| SCHEMBL13274683 | 0.81 | ACSS2 (0.41) | OPRM1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | claimed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | OXTR 4586/4885OPRM1 2711/4885AVPR1A 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.